If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
We are very pleased to announce the launch of the NOVELTY study, and are enthusiastic to be working with physicians and study centres around the world to increase our knowledge of obstructive lung disease on a global, local and individual patient level.
The NOVELTY study is truly innovative in the respiratory field, thanks to its broad inclusion criteria, large sample size of patients with asthma and/or COPD, wide geographical scope, longitudinal design and additional biomarker analysis. This will provide a deep understanding of patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, and will allow us to identify novel phenotypes and endotypes involved in asthma and COPD and provide insights into how the underlying disease mechanisms evolve with clinical progression. Recruitment of patients with newly diagnosed asthma and/or COPD also gives us a better opportunity to identify modifiable treatment targets.
The findings from the study have the potential to transform clinical practice, drive towards a more personalised treatment approach and thereby provide a positive impact on the lives of patients with obstructive lung disease.
In addition, the NOVELTY initiative reaches beyond the primary objectives of the study itself – the information collected will provide a real-world evidence data platform for the broader community of patients, physicians, payers, regulators and the scientific community for many years to come.
We hope that you will follow us as the study progresses over the forthcoming years.
Helen Reddel (Co-Chair of the NOVELTY Scientific Committee)
Woolcock Institute of Medical Research, Australia
Jørgen Vestbo (Former Co-Chair of the NOVELTY Scientific Committee)
University of Manchester, UK; University of Southern Denmark, Denmark